Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Investigating the safety and the activity of Rapamycin, administered before and during
preoperative radiotherapy in patients with an operable colorectal carcinoma. The phase I dose
escalation study will be performed in three steps (2, 4 and 6 mg). Patients entered in phase
II will follow the same tolerable treatment regimen as patients in phase I study.